Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 11.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and Twist Bioscience Corp for 27 Days on average.
| SGOV | TWST | |
|---|---|---|
Market Cap | $114.40B | $10.08B |
Volume | 18,879,081 | 4,229,037 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $205.00 |
52-Week Low | $100.28 | $25.45 |
Typical Hold Time | 50 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill holdings. The ETF shows bearish technical signals with 17 sell indicators versus 4 buy signals, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026. The fund continues its consistent dividend payments with recent distributions of $0.30-$0.31 per share.
SGOV provides exposure to ultra-short-term Treasury securities, offering stability amid bond market volatility. The ETF faces headwinds from rising interest rates but benefits from flight-to-quality flows. Key risks include interest rate sensitivity and potential yield compression if Fed policy shifts dovishly. Current technical weakness may present entry opportunities for income-focused investors seeking capital preservation.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
